乐
乐观
乐观 · 25%SMMT
$32.18
情景价格
$15.770
+0.453 (+2.87%)收盘时
Loading chart…
- 最高
- 15.800
- 开盘
- 15.190
- 成交量加权均价
- 15.55
- 成交量
- 3.32M
- 市值
- 5.52B
- 最低
- 15.069
- 成交额
- 51.56M
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
AI 分析 of Summit Therapeutics Inc (SMMT)
买入Summit Therapeutics Inc is a good buy right now due to its recent $2 billion investment from AstraZeneca, which provides a significant funding boost and a target price of $18.36 per share, representing a 19% premium over the current price of $15.47. Additionally, the forward P/E ratio of 3.72 indicates potential for growth compared to its current valuation. The main risk is the company's ongoing negative earnings, with an EPS estimate of -0.28 for the next quarter, which could impact investor sentiment if results do not meet expectations.
分析师评级（6）
上行空间 +169.44%
买入
6 买入
0 持有
0 卖出
当前: 15.77
最低
18.00
平均
42.49
最高
131.90
Barclays
Equal Weight
$20
2026-10-01
Barclays
2026-10-01
目标价
$20
Equal Weight
Citi
买入
$43
2026-09-29
Citi
2026-09-29
目标价
$43
买入
Jefferies
买入
$25
2026-09-09
Jefferies
2026-09-09
目标价
$25
买入
Bernstein
Market Perform
—
2026-08-25
Bernstein
2026-08-25
目标价
—
Market Perform
Leerink
Market Perform
$13
2026-08-12
Leerink
2026-08-12
目标价
$13
Market Perform
估值指标
Summit Therapeutics Inc（SMMT）当前预期市盈率为 3.72，5 年平均预期市盈率为 -20.32。
Alphio AI 对 SMMT 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
持有 SMMT 的大户
事件时间线
资讯
9.010-25NewsfilterFirst Regimen to Significantly Improve Survival in Biliary Tract Cancer
7.510-24PRnewswireLunit Partners with Summit for AI Pathology Research
- 7.510-24Newsfilter
Lunit and Summit Announce Research Agreement for AI Pathology in Immuno-Oncology
- 7.510-23Newsfilter
Summit and Lunit Announce Research Agreement for AI Pathology Analysis
- 9.010-22Newsfilter
Ivonescimab Clinical Data to Feature at ESMO 2026
SMMT 常见问题 —— 由 Alphio AI 解答
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Summit Therapeutics Inc is a good buy right now due to its recent $2 billion investment from AstraZeneca, which provides a significant funding boost and a target price of $18.36 per share, representing a 19% premium over the current price of $15.47. Additionally, the forward P/E ratio of 3.72 indicates potential for growth compared to its current valuation. The main risk is the company's ongoing negative earnings, with an EPS estimate of -0.28 for the next quarter, which could impact investor sentiment if results do not meet expectations.
6 analysts cover SMMT: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 42.49.
社区
更多 ↗
$SMMT just landed a major combo opportunity for ivonescimab — and Datroway is the key. Summit is teaming with AstraZeneca ($AZN) and Daiichi Sankyo to evaluate ivonescimab with Datroway, a TROP2-targeted ADC jointly developed and commercialized by Daiichi and AstraZeneca. The initial focus is a Phase III study in first-line TNBC, while the collaboration plans to evaluate the combo across multiple solid tumors, including breast and lung cancers. Latest SMMT news here
展开
$SMMT $AZN Citi raised its price target on Summit Therapeutics (SMMT) to $43 from $40 and keeps a Buy rating on the shares after the company announced a $2B investment from AstraZeneca (AZN). AstraZeneca's $2B investment in convertible preferred shares is equivalent to $18.36 per common share, representing a 19% premium to Summit's latest closing price, the analyst tells investors in a research note. Citi views the deal as a "de-risking event" that removes Summit's financing overhang.
展开
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says. A tidal wave of innovation in biotechnology is improving patient outcomes, transforming the industry's prospects, and lifting long-suffering biotech shares. Spurred by therapeutic breakthroughs and new-product launches, investors have bid up the iShares Biotechnology, or IBB, by 24% this year, while the State Street SPDR S&P Biotech ETF, or XBI, has risen 28%, more than twice the gain of the S&P 500. Large pharmaceutical companies are also paying attention. They have been striking licensing deals with smaller biotechs and scooping up whole companies in a bid to rebuild their pipelines and replace blockbuster drugs facing patent expirations. $MRNA $MRK $RVMD $BMY $SMMT
展开本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。